UOB bank
With the aging global population, growing middle class and rise of emerging markets, the healthcare sector has seen a corresponding leap in demand for modern biopharmaceuticals and medical services. Such demographic shifts have spurred the healthcare sector to greater levels of innovation in the Fourth Industrial Revolution or Industry 4.0, one that is characterised by rapid and discrete technological advances. The progress in medical data management has enabled the development of newfangled techniques, new ways of formulating drugs and vaccines which will inject new lifeblood to revitalise the post-coronavirus economy.
For the Literature Digest this month, we look into how medical and healthcare innovations have enhanced medical procedures, technologies, discoveries and reshaped the sector as we know it. Check out the following articles/videos:
Changing Demographics demand Healthcare reforms (PWC)
If a coronavirus vaccine passes human trials, how does it get approved? (SCMP)
3D printed drugs could be a Godsend for those on multiple pills a day and potentially life-saving (The Conversation)
The hospital of the future looks nothing like todays (Fast Company)
Understand when telemedicine works and when it doesn’t (TODAY)
Green Shoots
As part of UOBAM’s continued efforts to promote sustainability and Environmental, Social and Governance (ESG) in our approach to investing and our company’s culture, here are also some articles in our Green Shoots segment.
Pandemic Creates Watershed Moment for Sustainable Investing (CIO)
Sustaining the performance of shariah funds (The Edge)
This publication shall not be copied or disseminated, or relied upon by any person for whatever purpose. The information herein is given on a general basis without obligation and is strictly for information only. This publication is not an offer, solicitation, recommendation or advice to buy or sell any investment product, including any collective investment schemes or shares of companies mentioned within. Although every reasonable care has been taken to ensure the accuracy and objectivity of the information contained in this publication, UOB Asset Management Ltd ("UOBAM") and its employees shall not be held liable for any error, inaccuracy and/or omission, howsoever caused, or for any decision or action taken based on views expressed or information in this publication. The information contained in this publication, including any data, projections and underlying assumptions are based upon certain assumptions, management forecasts and analysis of information available and reflects prevailing conditions and our views as of the date of this publication, all of which are subject to change at any time without notice. Please note that the graphs, charts, formulae or other devices set out or referred to in this document cannot, in and of itself, be used to determine and will not assist any person in deciding which investment product to buy or sell, or when to buy or sell an investment product. UOBAM does not warrant the accuracy, adequacy, timeliness or completeness of the information herein for any particular purpose, and expressly disclaims liability for any error, inaccuracy or omission. Any opinion, projection and other forward-looking statement regarding future events or performance of, including but not limited to, countries, markets or companies is not necessarily indicative of, and may differ from actual events or results. Nothing in this publication constitutes accounting, legal, regulatory, tax or other advice. The information herein has no regard to the specific objectives, financial situation and particular needs of any specific person. You may wish to seek advice from a professional or an independent financial adviser about the issues discussed herein or before investing in any investment or insurance product. Should you choose not to seek such advice, you should consider carefully whether the investment or insurance product in question is suitable for you.